Similar articles for PMID: 26912426

Year	Number of Results
2004	1
2005	1
2012	1
2013	2
2014	3
2015	5
2016	25
2017	24
2018	20
2019	3
2020	4
2021	3
2022	1
2023	0

1

Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.

Kwekkeboom D. Kwekkeboom D. J Nucl Med. 2016 Jul;57(7):1002-3. doi: 10.2967/jnumed.115.171363. Epub 2016 Feb 18. J Nucl Med. 2016. PMID: 26912426 Free article. No abstract available.

2

Re: ²²⁵Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer.

Hadaschik B. Hadaschik B. Eur Urol. 2016 Dec;70(6):1080-1081. doi: 10.1016/j.eururo.2016.08.028. Epub 2016 Aug 21. Eur Urol. 2016. PMID: 27554243 No abstract available.

3

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. Kratochwil C, et al. J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16. J Nucl Med. 2016. PMID: 26985056 Free article. Clinical Trial.

4

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.

Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, Bögemann M. Rahbar K, et al. Clin Nucl Med. 2016 Jul;41(7):522-8. doi: 10.1097/RLU.0000000000001240. Clin Nucl Med. 2016. PMID: 27088387

5

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Yadav MP, et al. Nucl Med Commun. 2017 Jan;38(1):91-98. doi: 10.1097/MNM.0000000000000606. Nucl Med Commun. 2017. PMID: 27782913

6

¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.

Czernin J, Calais J. Czernin J, et al. J Nucl Med. 2021 Aug 1;62(8):1025-1026. doi: 10.2967/jnumed.121.262710. Epub 2021 Jun 24. J Nucl Med. 2021. PMID: 34330737 Free article. No abstract available.

7

[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].

Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P, Krause BJ. Fendler WP, et al. Nuklearmedizin. 2016 Jun 28;55(3):123-8. Nuklearmedizin. 2016. PMID: 27350005 German.

8

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. Kratochwil C, et al. J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7. J Nucl Med. 2016. PMID: 27390158 Free article.

9

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Kabasakal L, et al. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. Epub 2015 Jul 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 26227531

10

Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Wei X, et al. Clin Nucl Med. 2017 Sep;42(9):704-706. doi: 10.1097/RLU.0000000000001763. Clin Nucl Med. 2017. PMID: 28719450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed